A randomized, double-blind, phase ii study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2382-2389

  Groen, H J M ^a   Socinski, M A ^b   Grossi, F ^c   Juhasz, E ^d   Gridelli, C ^e   Baas, P ^f   Butts, C A ^g   Chmielowska, E ^h   Usari, T ⁱ   Selaru, P ^j   Harmon, C ^j   Williams, J A ^k   Gao, F ^k   Tye, L ^k   Chao, R C ^k   Blumenschein Jr , G R ^l  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^e S G MOSCATI HOSPITAL   (Italy)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g CROSS CANCER INSTITUTE   (Canada)

^h Oncology Centre of Prof Franciszka ukaszczyka Memorial Hospital   (Poland)

ⁱ PFIZER INC   (United States)

^j Atrium Staffing Inc   (United States)

^k Pf Izer Oncology Inc   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Combination therapy; Efficacy; Erlotinib; Non small cell lung cancer; Safety; Sunitinib

Indexed keywords

ERLOTINIB; K RAS PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RNA; SUNITINIB; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACNE; ACUTE PANCREATITIS; ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DERMATITIS ACNEIFORM; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; ESOPHAGITIS; EXFOLIATIVE RASH; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISCHEMIA; LUNG ALVEOLUS PROTEINOSIS; LUNG EDEMA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEPTIC ULCER BLEEDING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

COMBINATION THERAPY; EFFICACY; ERLOTINIB; NON-SMALL-CELL LUNG CANCER; SAFETY; SUNITINIB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 84883360843     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt212     Document Type: Article

References (33)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel'carboplatin alone or with bevacizumab for non-small-cell lung cancer. J Thorac Oncol 2008; 3: Abstract p. S302.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92'98.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated nonsmall- cell lung cancer. N Engl J Med 2005; 353(2): 123'132.
4. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in nonsmall- cell lung cancer. Br J Cancer 2000; 82(8): 1427'1432.
5. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003; 36(1): 49'59.
6. Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21(2): 154'165.
7. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214(3): 559'567.
8. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2(5): 471'78.
9. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91(10): 4070'4076.
10. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327'337.
11. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF- 1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20(8): 757'766.
12. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101(9): 3597'3605.
13. Pfizer Inc. Data on file. 2011.
14. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101(9): 1543'1548.
15. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26 (4): 650'656.
16. Govindan R, Blumenschein G, Jr, Groen HJM, et al. Phase III trial of sunitinib and erlotinib in advanced/metastatic non-small cell lung cancer. Presented at the 3rd Latin American Conference on Lung Cancer, Vina del Mar, Chile, October 9'10, 2008.
17. Blumenschein GR, Ciuleanu T, Robert F, et al. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): A lead-in study. J Thorac Oncol 2012; 7: 1406'1416.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205'216.
19. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non'small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070'2078.
20. Herbst RS, Blumenschein G, Kim E, et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol 2010; 28: 15s.
21. Ramos AH, Dutt A, Mermel C, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009; 8(21): 2042'2050.
22. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10(8): 794'800.
23. DePrimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.
24. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45(11): 1959'1968.
25. Harmon C, Figlin R, Hutson T, et al. Circulating protein biomarkers of sunitinib (SU) and interferon-a (IFN-a) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011; 29(suppl): 10525.
26. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26(22): 3743'3748.
27. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: 1059'1066.
28. De Boer R, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the secondline treatment of advanced non-small cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067'1074.
29. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11(7): 619'626.
30. Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114'1121.
31. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23(11): 2544'2555.
32. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007; 25(30): 4743'4750.
33. Herbst R, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1846'1854.